Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.

Roberts JS, Christensen KD, Green RC.

Clin Genet. 2011 Nov;80(5):407-14. doi: 10.1111/j.1399-0004.2011.01739.x. Epub 2011 Jul 18. Review.

2.

Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.

Cassidy MR, Roberts JS, Bird TD, Steinbart EJ, Cupples LA, Chen CA, Linnenbringer E, Green RC.

Alzheimers Dement. 2008 Nov;4(6):406-13. doi: 10.1016/j.jalz.2008.04.007.

3.

Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.

Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC.

Health Aff (Millwood). 2005 Mar-Apr;24(2):483-90.

4.

Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study.

Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC; REVEAL (Risk Evaluation and Education for Alzheimer's Disease) Study Group.

J Geriatr Psychiatry Neurol. 2005 Dec;18(4):250-5.

PMID:
16306249
5.

Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility.

Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC.

Genet Test Mol Biomarkers. 2011 Dec;15(12):871-5. doi: 10.1089/gtmb.2011.0028. Epub 2011 Jul 12.

6.

The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study.

Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC.

Eur J Hum Genet. 2010 Dec;18(12):1296-301. doi: 10.1038/ejhg.2010.119. Epub 2010 Jul 28.

7.

Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Roberts JS, Uhlmann WR.

Prog Neurobiol. 2013 Nov;110:89-101. doi: 10.1016/j.pneurobio.2013.02.005. Epub 2013 Apr 9. Review.

8.

Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial.

Roberts JS, Barber M, Brown TM, Cupples LA, Farrer LA, LaRusse SA, Post SG, Quaid KA, Ravdin LD, Relkin NR, Sadovnick AD, Whitehouse PJ, Woodard JL, Green RC.

Genet Med. 2004 Jul-Aug;6(4):197-203.

PMID:
15266207
9.

A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.

Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ, Royal CD, Obisesan TO, Cook-Deegan R, Linnenbringer E, Butson MB, Fasaye GA, Levinson E, Roberts JS; REVEAL Study Group.

Alzheimers Dement. 2015 Oct;11(10):1222-30. doi: 10.1016/j.jalz.2014.10.014. Epub 2014 Dec 9.

10.

Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease.

Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC.

J Health Commun. 2009 Dec;14(8):768-84. doi: 10.1080/10810730903295518.

11.

Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease.

Roberts JS, Chen CA, Uhlmann WR, Green RC.

Genet Med. 2012 Aug;14(8):742-8. doi: 10.1038/gim.2012.37. Epub 2012 Apr 12.

12.

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.

Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC.

Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):94-7. doi: 10.1097/WAD.0b013e31815a9dcc.

13.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
14.
15.

Predictive genetic testing for Alzheimer's disease: impact upon risk perception.

Marteau TM, Roberts S, LaRusse S, Green RC.

Risk Anal. 2005 Apr;25(2):397-404.

PMID:
15876213
16.

Recall of disclosed apolipoprotein E genotype and lifetime risk estimate for Alzheimer's disease: the REVEAL Study.

Eckert SL, Katzen H, Roberts JS, Barber M, Ravdin LD, Relkin NR, Whitehouse PJ, Green RC.

Genet Med. 2006 Dec;8(12):746-51.

PMID:
17172937
17.

Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk.

Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB.

Patient Educ Couns. 2006 Dec;64(1-3):259-67. Epub 2006 Jul 21.

PMID:
16860524
18.

[Attitudes towards predictive genetic testing for Alzheimer's disease].

Illes F, Bernhardt T, Prell K, Rietz C, Rudinger G, Frölich L, Maier W, Rietschel M.

Z Gerontol Geriatr. 2006 Jun;39(3):233-9. German.

PMID:
16794889
19.

Factors affecting recall of different types of personal genetic information about Alzheimer's disease risk: the REVEAL study.

Besser AG, Sanderson SC, Roberts JS, Chen CA, Christensen KD, Lautenbach DM, Cupples LA, Green RC.

Public Health Genomics. 2015;18(2):78-86. doi: 10.1159/000368888. Epub 2015 Jan 24.

20.

Translational research in genomics of Alzheimer's disease: a review of current practice and future perspectives.

Mihaescu R, Detmar SB, Cornel MC, van der Flier WM, Heutink P, Hol EM, Rikkert MG, van Duijn CM, Janssens AC.

J Alzheimers Dis. 2010;20(4):967-80. doi: 10.3233/JAD-2010-1410. Review.

PMID:
20182048

Supplemental Content

Support Center